ALX Oncology Holdings Inc.

6.38-1.13-15.05%Vol 3.46M1Y Perf -28.61%
Oct 4th, 2023 16:00 DELAYED
BID6.23 ASK6.52
Open7.12 Previous Close7.51
Pre-Market- After-Market6.54
 - -  0.16 2.51%
Target Price
35.50 
Analyst Rating
Strong Buy 1.29
Potential %
456.43 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★★★     56.37
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
25.19 
Earnings Rating
Market Cap262.55M 
Earnings Date
14th Nov 2023
Alpha-0.03 Standard Deviation0.26
Beta1.57 

Today's Price Range

6.017.45

52W Range

3.9413.64

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
28.89%
1 Month
40.22%
3 Months
-12.48%
6 Months
45.66%
1 Year
-28.61%
3 Years
-81.66%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ALXO6.38-1.1300-15.05
AAPL173.661.26000.73
GOOG136.272.97002.23
MSFT318.965.56501.78
XOM111.50-4.3300-3.74
WFC38.970.30000.78
JNJ155.520.18000.12
FB196.640.99000.51
GE108.851.09001.01
JPM143.350.64000.45
Financial StrengthValueIndustryS&P 500US Markets
11.30
11.50
0.02
0.02
-40 409.70
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
9.10
-10 177.40
-10 159.60
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2023-0.85-0.841.18
Q01 2023-0.84-0.5830.95
Q04 2022-0.91-0.7517.58
Q03 2022-0.90-0.873.33
Q02 2022-0.66-0.81-22.73
Q01 2022-0.77-0.6022.08
Q04 2021-0.77-0.709.09
Q03 2021-0.47-0.61-29.79
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date14th Nov 2023
Estimated EPS Next Report-0.86
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume3.46M
Shares Outstanding41.15K
Shares Float15.88M
Trades Count29.74K
Dollar Volume22.71M
Avg. Volume3.86M
Avg. Weekly Volume8.58M
Avg. Monthly Volume2.17M
Avg. Quarterly Volume817.42K

ALX Oncology Holdings Inc. (NASDAQ: ALXO) stock closed at 6.38 per share at the end of the most recent trading day (a -15.05% change compared to the prior day closing price) with a volume of 3.46M shares and market capitalization of 262.54M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 15 people. ALX Oncology Holdings Inc. CEO is Jaume Pons.

The one-year performance of ALX Oncology Holdings Inc. stock is -28.61%, while year-to-date (YTD) performance is -43.39%. ALXO stock has a five-year performance of %. Its 52-week range is between 3.9357 and 13.64, which gives ALXO stock a 52-week price range ratio of 25.19%

ALX Oncology Holdings Inc. currently has a PE ratio of -3.70, a price-to-book (PB) ratio of 1.56, a price-to-sale (PS) ratio of 4 072.61, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -33.79%, a ROC of -35.39% and a ROE of -36.07%. The company’s profit margin is -%, its EBITDA margin is -10 159.60%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from ALX Oncology Holdings Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.86 for the next earnings report. ALX Oncology Holdings Inc.’s next earnings report date is 14th Nov 2023.

The consensus rating of Wall Street analysts for ALX Oncology Holdings Inc. is Strong Buy (1.29), with a target price of $35.5, which is +456.43% compared to the current price. The earnings rating for ALX Oncology Holdings Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ALX Oncology Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ALX Oncology Holdings Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 10.97, ATR14 : 0.56, CCI20 : 616.75, Chaikin Money Flow : -0.12, MACD : 0.16, Money Flow Index : 98.69, ROC : 44.98, RSI : 78.86, STOCH (14,3) : 77.99, STOCH RSI : 1.00, UO : 66.72, Williams %R : -22.01), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ALX Oncology Holdings Inc. in the last 12-months were: Garcia Peter (Sold 893 shares of value $9 886 ), Jaume Pons (Sold 3 232 shares of value $35 779 ), Peter S. Garcia (Sold 893 shares of value $9 886 ), Pinto Shelly (Sold 482 shares of value $5 336 ), Pons Jaume (Sold 3 232 shares of value $35 778 ), Randolph Sophia (Option Excercise at a value of $48 171), Randolph Sophia (Sold 1 617 shares of value $17 900 ), Shelly Pinto (Sold 482 shares of value $5 336 ), Sophia Randolph (Option Excercise at a value of $189 875), Sophia Randolph (Sold 1 617 shares of value $17 901 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (85.71 %)
6 (85.71 %)
6 (85.71 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (14.29 %)
1 (14.29 %)
1 (14.29 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.29
Strong Buy
1.29
Strong Buy
1.29

ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company. The firm is focused on developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system.

CEO: Jaume Pons

Telephone: +1 650 466-7125

Address: 866 Malcolm Road, Burlingame 94010, CA, US

Number of employees: 15

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

63%37%

 

TipRanks News for ALXO


News

Stocktwits